

For **reauthorization**:

Elevidys is a one-time single infusion and will not be reauthorized.

CareSource considers Elevidys (delandistrogene moxeparvovec-rokl) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
07/18/2023	New policy for Elevidys created.

References:

1. Elevidys [package insert]. Cambridge, MA; Sarepta Therapeutics, Inc. 2023.
2. Birnkrant DJ, Bushby K, Bann CM, et al. Dia t